HIV Monitoring: Essential Laboratory Tests for Patients

Regular laboratory monitoring is critical for managing HIV infection, assessing treatment efficacy, and preventing complications.

Core Monitoring Tests

1. HIV Viral Load (HIV-1 RNA)

  • Measures viral replication level in blood
  • Goal: Undetectable (<50 copies/mL) on ART
  • Frequency: At diagnosis, 2-4 weeks after ART initiation, then every 3-6 months
  • Detects virologic failure early

2. CD4+ T-Cell Count

  • Measures immune system strength
  • <500 cells/µL: Immune suppression; <200: AIDS-defining
  • Frequency: At diagnosis, every 3-6 months (less frequent if stable on ART)
  • Guides opportunistic infection prophylaxis

3. Complete Blood Count (CBC)

  • Red blood cells (anemia), white blood cells (infection risk), platelets (bleeding risk)
  • Monitor for ART toxicity (zidovudine → anemia/neutropenia)
  • Frequency: Every 3-6 months

4. Liver Function Tests (LFTs)

  • ALT, AST, ALP, bilirubin, albumin
  • Monitor for ART hepatotoxicity (NNRTIs, PIs), viral hepatitis coinfection, fatty liver
  • Frequency: Every 3-6 months

5. Renal Function Tests

  • Creatinine, eGFR, BUN
  • Monitor for tenofovir (TDF) nephrotoxicity, HIV-associated nephropathy (HIVAN)
  • Frequency: Every 3-6 months (more often if risk factors)

6. Lipid Profile

  • Total cholesterol, LDL, HDL, triglycerides
  • ART (especially PIs) can cause dyslipidemia → cardiovascular risk
  • Frequency: Baseline, then annually or more often if abnormal

7. Hepatitis B & C Serology

  • HBsAg, anti-HBc, anti-HBs (HBV); anti-HCV, HCV RNA (HCV)
  • Coinfection affects ART selection and liver disease progression
  • Test at baseline; vaccinate if HBV susceptible

8. Drug Resistance Testing

  • Genotypic resistance assay (standard)
  • At baseline, virologic failure, pre-conception
  • Guides ART regimen selection

9. HIV Genotyping/Subtyping

  • Identifies HIV-1 subtype (B predominant in US/EU; non-B globally)
  • May influence drug resistance patterns and treatment choices

Additional Monitoring

  • Urinalysis (proteinuria for HIVAN/tenofovir)
  • Bone density (DEXA) for older adults/long-term ART
  • Cardiovascular risk assessment
  • STI screening (syphilis, gonorrhea, chlamydia)
  • Cancer screening per guidelines

Testing frequency individualized based on clinical status, treatment phase, and guidelines (DHHS, IAS-USA, WHO).

HIV & AIDS - Related Articles